Novartis Restructure Sees Drug Development And Oncology Chiefs Exit

Aims To Boost R&D And Commercial Performance

Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.

Novartis_Building — Novartis aims to save $1bn over the next few years, and find more transformational new medicines from inside and outside its own R&D operations. • Source: Getty Images

Novartis has unveiled a major restructuring and streamlining of its global business, aimed at making it more competitive commercially and in R&D, that also sees the departure of oncology leader Susanne Schaffert and head of drug development John Tsai.

The changes announced on 4 April had not been flagged in advance by the Swiss pharma giant, but do not...